Haw Par Corp Ltd (HAWPF)
8.35
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.848B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 22.41% |
| Valuation | |
| PE Ratio | 10.66 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 10.45 |
| Price to Book Value | 0.6786 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.1532 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0098 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 36.44% |
Profile
| Haw Par Corp Ltd is a major drug manufacturing company that operates multiple brands. The company's primary strategy is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, and Others segment. The company generates maximum revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brand. Geographically, it generates a majority of its revenue from the ASEAN countries. |
| URL | https://www.hawpar.com |
| Investor Relations URL | https://hawpar.listedcompany.com/ir.html |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 22, 2024 |
Ratings
Profile
| Haw Par Corp Ltd is a major drug manufacturing company that operates multiple brands. The company's primary strategy is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, and Others segment. The company generates maximum revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brand. Geographically, it generates a majority of its revenue from the ASEAN countries. |
| URL | https://www.hawpar.com |
| Investor Relations URL | https://hawpar.listedcompany.com/ir.html |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 22, 2024 |